Promomed Q2 2026: Revenue +75.7% YoY, EBITDA +88.7%, Net Profit +82.6%; Growth Broadly Stable vs H1
Promomed reported Q2 2026 revenue of RUB 11,398.8 mln, EBITDA of RUB 3,897.7 mln and net profit of RUB 1,294.3 mln, up +75.7%, +88.7% and +82.6% YoY respectively. Revenue growth was broadly stable versus the previous half (H1 2026 also +75.7% YoY), while EBITDA growth was likewise broadly stable at +88.7% YoY.
Q2 2026 vs Q2 2025: headline YoY growth
What drove the result
EBITDA grew faster than revenue (+88.7% vs +75.7% YoY), pointing to operating leverage: EBITDA margin expanded to 34.2% in Q2 2026 from 31.8% in Q2 2025. Net profit rose +82.6% YoY to RUB 1,294.3 mln, with net margin at 11.4% versus 10.9% a year earlier. On a sequential basis, Q2 2026 revenue of RUB 11,398.8 mln was broadly in line with Q4 2025's RUB 12,299.0 mln, while EBITDA of RUB 3,897.7 mln compared with RUB 5,476.3 mln in Q4 2025.
Key figures
| Metric | Q2 2025 | Q2 2026 | Change |
|---|---|---|---|
| Revenue, RUB mln | 6,487.7 | 11,398.8 | +75.7% |
| EBITDA, RUB mln | 2,065.5 | 3,897.7 | +88.7% |
| Net profit, RUB mln | 709.0 | 1,294.3 | +82.6% |
| EBITDA margin | 31.8% | 34.2% | +2.4 pp |
| Net margin | 10.9% | 11.4% | +0.5 pp |
Outlook
The key read is margin expansion: EBITDA margin of 34.2% in Q2 2026 versus 31.8% a year earlier shows the top-line surge is translating into operating leverage. With H1 2026 revenue of RUB 22,796.8 mln and EBITDA of RUB 7,795.7 mln, the company enters H2 with strong momentum. Watch whether the EBITDA margin holds above 34% and whether net margin can build on the 11.4% level as revenue scales.
Open the company's financial profile PRMD →
See also: market overview · valuation map · stock screeners